A Randomized, Double-blind, Multicentre, Placebo-controlled, Proof-of-concept Clinical Trial Evaluating the Safety and Efficacy of the Biased Melanocortin Agonist AP1189 Versus Placebo as an add-on to Standard of Care (SOC) in Participants With RESPIRatory Insufficiency Expected to be Caused by Infection With Respiratory Viruses, Including Influenza, Respiratory Syncytial Virus, and Coronavirus

A clinical study to evaluate the efficacy and safety of once daily oral dosing of 100 mg AP1189 or placebo administered for 14 days, as an add-on to standard of care (SOC) in participants with respiratory insufficiency expected to be caused by respiratory viral infection.

开始日期2026-05-01

申办/合作机构

SynAct Pharma ApS

CTIS2026-525343-33-00

/ Not yet recruiting临床2期

A randomized, double blind, placebo-controlled, phase II, multicentre trial to explore the efficacy and safety of oral AP1189 tablets administered at the dose 100 mg/day for 12 weeks in patients diagnosed with polymyalgia rheumatica and in remission on glucocorticoid

开始日期2026-02-02

申办/合作机构

SynAct Pharma ApS

NCT06917001

/ Not yet recruiting临床2期IIT

A Randomized, Double-blind, Placebo-controled, Phase 2a Trial Evaluating the Safety and Initial Efficacy of Resomelagon in Patients With Dengue Infection

The goal of this clinical trial is to understand if Resomelagon can treat adult patients with Dengue virus infection. The main questions the investigators aim to answer are:
Is Resomelagon safe to use in patients with Dengue? Is Resomelagon able to reduce the duration of illness? (defined by clinical and laboratory criteria) Participants will be allocated to Resomelagon or placebo groups in this study and asked to take the medication and submitted to blood tests.

开始日期2026-02-01

申办/合作机构

Universidade Federal de Minas Gerais

100 项与 Resomelagon 相关的临床结果

登录后查看更多信息

100 项与 Resomelagon 相关的转化医学

登录后查看更多信息

100 项与 Resomelagon 相关的专利（医药）

登录后查看更多信息

项与 Resomelagon 相关的文献（医药）

2025-11-01·PHYTOMEDICINE

Baicalin ameliorates high-fat diet induced MAFLD by inhibiting ERK/PPARγ/CD36 pathway

Article

作者: Liu, Hanqiang ; Xu, Xiaona ; Gao, Peipei ; Su, Zheng ; Wang, Xiaohui ; Li, Yuting ; Zhang, Xianjiao ; Li, Mengying ; Zhang, Lei ; Lei, Jiamin

OBJECTIVE:

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a global health concern with limited therapeutic options. Baicalin (BA), a natural flavonoid, has shown promise in ameliorating lipid metabolism and liver function. This study employed an integrated strategy combining network pharmacology, molecular docking, and in vivo/in vitro validation to elucidate the novel protective mechanism of BA against MAFLD through modulation of the ERK/PPARγ/CD36 signaling axis in high-fat diet (HFD)-induced mice.

METHODS:

Potential targets of BA and MAFLD were identified from multiple databases, with common targets screened via Venn analysis. A protein-protein interaction (PPI) network was constructed and visualized based on degree values. Gene Ontology (GO) and KEGG pathway enrichment analyses were conducted using R software. Molecular docking and surface plasmon resonance (SPR) experiments were performed to evaluate the binding affinity of BA to key targets, and a positive control was also added. For the in vivo study, MAFLD was induced in mice via 16-week HFD. Body weight, average food intake, glucose metabolism (GTT, ITT), serum lipid metabolism indexes (TG, TC, HDL-C, LDL-C), and serum liver function markers (ALT, AST, ALP, GGT) were assessed. Hepatic lipid deposition was analyzed using H&E, oil red O staining and NAS score. The protein and mRNA expression of p-ERK, PPARγ, CD36, SREBP-1c, FAS, ACC, and SCD1 were examined by Western blot or RT-PCR, with CD36 expression was further confirmed by immunofluorescence. In vitro, cell viability was measured using CCK8 at 12, 24, and 48 h after BA treatment. LO2 cells were treated with BA, free fatty acids (FFA), SCH772984 (a p-ERK inhibitor), or resomelagon (a p-ERK agonist), and lipid accumulation and protein expression were evaluated using Western blot and oil red O staining.

RESULTS:

Network pharmacology analysis identified 37 common targets between BA and MAFLD, with PPARγ confirmed as a high-affinity BA target by molecular docking (pKi = -11.6096 µM) and SPR (K_D = 6.84 × 10^-7 M). In vivo, BA significantly reduced body weight (p < 0.05) and improved glucose metabolism (p < 0.05), lowered serum TG, TC, LDL-C levels (p < 0.05) and pro-inflammatory cytokines IL-1β, IL-6, TNF-α levels (p < 0.05). Additionally, BA attenuated hepatic steatosis and downregulated the expression levels of p-ERK, PPARγ and CD36 in liver tissues (p < 0.05). In vitro, BA or SCH772984 inhibited p-ERK, PPARγ, and CD36 expression (p < 0.05), as well as lipid accumulation in FFA-treated LO2 cells (p < 0.05). The resomelagon-treated cells were consistent with the effect of FFA, while BA could reverse the effects (p < 0.05).

CONCLUSION:

This study by using integrates computational prediction demonstrated that PPARγ was the main target of BA, then with multi-level experimental validation, elucidated that BA could ameliorate MAFLD by modulating core ERK/PPARγ/CD36 signaling pathway, highlighting a novel therapeutic target for MAFLD.

2024-12-01·British Journal of Pharmacology

Effects of a pro‐resolving drug in COVID‐19: preclinical studies to a randomized, placebo‐controlled, phase Ib/IIa trial in hospitalized patients

Article

作者: Silva, Barbara L. V. ; Costa, Vivian V. ; Almeida, Pedro R. J. ; Milhorato, Larissa B. ; Queiroz‐Junior, Celso M. ; Jonassen, Thomas E. N. ; Teixeira, Danielle C. ; Teixeira, Mauro M. ; Periard, Alexandre M. ; Fonseca, Talita C. M. ; Tana, Fernanda L. ; Perretti, Mauro ; Avila, Renata E. ; Serufo, Angela V. ; Alcantara, Katlen M. M. ; Resende, Carolina B. ; Santos, Felipe R. ; Souza, Renan P.

Introduction:

Pro‐resolving molecules may curb disease caused by viruses without altering the capacity of the host to deal with infection. AP1189 is a melanocortin receptor‐biased agonist endowed with pro‐resolving and anti‐inflammatory activity. We evaluated the preclinical and early clinical effects of treatment with AP1189 in the context of COVID‐19.

Methods:

C57BL/6j mice were infected intranasally with MHV‐A59 or hK18‐ACE2 mice with SARS‐CoV‐2. AP1189 (10 mg·kg−1, BID, s.c.) was given to the animals from day 2 and parameters evaluated at day 5. Human PBMCs from health donors were infected with SARS‐CoV‐2 in presence or absence of AP1189 and production of cytokines quantified. In the clinical study, 6 patients were initially given AP1189 (100 mg daily for 14 days) and this was followed by a randomized (2:1), placebo‐controlled, double‐blind trial that enrolled 54 hospitalized COVID‐19 patients needing oxygen support. The primary outcome was the time in days until respiratory recovery, defined as a SpO2 ≥ 93% in ambient air.

Results:

Treatment with AP1189 attenuated pulmonary inflammation in mice infected with MHV‐A59 or SARS‐CoV‐2 and decreased the release of CXCL10, TNF‐α and IL‐1β by human PBMCs. Hospitalized COVID‐19 patients already taking glucocorticoids took a median time of 6 days until respiratory recovery when given placebo versus 4 days when taking AP1189 (P = 0.017).

Conclusion:

Treatment with AP1189 was associated with less disease caused by beta‐coronavirus infection both in mice and in humans. This is the first demonstration of the effects of a pro‐resolving molecule in the context of severe infection in humans.

2015-04-01·Journal of immunology (Baltimore, Md. : 1950)2区 · 医学

Biased Agonism as a Novel Strategy To Harness the Proresolving Properties of Melanocortin Receptors without Eliciting Melanogenic Effects

2区 · 医学

Article

作者: Gobbetti, Thomas ; Perretti, Mauro ; Jonassen, Thomas E N ; Montero-Melendez, Trinidad ; Cooray, Sadani N

Abstract:

There is a need for novel approaches to control pathologies with overexuberant inflammatory reactions. Targeting melanocortin (MC) receptors represents a promising therapy for obesity and chronic inflammation, but lack of selectivity and safety concerns limit development. A new way to increase selectivity of biological effects entails the identification of biased agonists. In this study, we characterize the small molecule AP1189 as a biased agonist at receptors MC1 and MC3. Although not provoking canonical cAMP generation, AP1189 addition to MC1 or MC3, but not empty vector, transfected HEK293 cells caused ERK1/2 phosphorylation, a signaling responsible for the proefferocytic effect evoked in mouse primary macrophages. Added to macrophage cultures, AP1189 reduced cytokine release, an effect reliant on both MC1 and MC3 as evident from the use of Mc1r−/− and Mc3r−/− macrophages. No melanogenesis was induced by AP1189 in B16-F10 melanocytes. In vivo, oral AP1189 elicited anti-inflammatory actions in peritonitis and, upon administration at the peak of inflammation, accelerated the resolution phase by ∼3-fold. Finally, given the clinical efficacy of adrenocorticotropin in joint diseases, AP1189 was tested in experimental inflammatory arthritis, where this biased agonist afforded significant reduction of macroscopic and histological parameters of joint disruption. These proof-of-concept analyses with AP1189, an active oral anti-inflammatory and resolution-promoting compound, indicate that biased agonism at MC receptors is an innovative, viable approach to yield novel anti-inflammatory molecules endowed with a more favorable safety profile.

项与 Resomelagon 相关的新闻（医药）

2026-08-27

·synactpharma.com

SynAct Pharma publishes Q2 2026 interim results

SynAct Pharma AB (publ) (“SynAct”) today publishes the interim report for the second quarter 2026. “With new capital secured and active partnering discussions underway, we are positioned to pursue the right deals and move these opportunities forward.” Jeppe Øvlesen, Chief Executive Officer Second quarter 2026 (April – June) The Group’s net sales amounted to SEK 0 (0) thousand. Operating expenses amounted to SEK 24,556 (30,345) thousand, a decrease of 19%. The Group’s loss after tax amounted to SEK 22,032 (27,522) thousand. The Group’s earnings per share before and after dilution amounted to -0.39 (-0.56) SEK. Cash flow from operating activities amounted to SEK -34,541 (-18,788) thousand. Cash flow from financing activities amounted to SEK -3,082 (35,969) thousand. Cash flow for the period amounted to SEK -51,517 (17,181) thousand. Cash and cash equivalents at the end of the period amounted to SEK 14,288 (68,890) thousand. First six months 2026 (January – June) The Group’s net sales amounted to SEK 0 (0) thousand. Operating expenses amounted to SEK 55,113 (58,443) thousand, a decrease of 6%. The Group’s loss after tax amounted to SEK 47,519 (52,207) thousand. The Group’s earnings per share before and after dilution amounted to -0.87 (-1.07) SEK. Cash flow from operating activities amounted to SEK -67,492 (-47,614) thousand. Cash flow from financing activities amounted to SEK 42,225 (55,672) thousand. Cash flow for the period amounted to SEK -39,161 (8,058) thousand. Significant events during the second quarter APR 23 – SynAct Pharma’s Nomination Committee ahead of the 2026 Annual General Meeting MAY 6 – SynAct Pharma completes dosing for last patient in Phase 2b ADVANCE study JUN 11 – Report from the 2026 Annual General Meeting of SynAct Pharma AB (publ) JUN 12 – SynAct obtains key US patent for resomelagon securing exclusivity until 2044 JUN 15 – Phase 2b ADVANCE study demonstrates positive effects of resomelagon in Rheumatoid Arthritis – supports phase 3 design, regulatory interactions, and partnering and SynAct Pharma Board of Directors and Management Enter Lock-up Agreements JUN 29 – BIO International USA confirms growing interest in resomelagon and SynAct Pharma following the positive effects of the ADVANCE study Significant events after the end of the period JUL 9 – Resomelagon shows reduced inflammation and joint damage in osteoarthritis model 20 JUL – SynAct Pharma strengthens financial position and strategic flexibility to advance partnering discussions and Phase III readiness AUG 5 – SynAct Pharma receives favorable US patent decision for immediate-release resomelagon tablet formulation AUG 19 – SynAct Pharma progresses first commercial agreement on resomelagon for treatment of dengue in Brazil – term sheet signed The full report is attached as PDF and is available on the company’s website: https://www.synactpharma.com/en/investors/financial-reports/ For further information, please contact: Jeppe Øvlesen CEO, SynAct Pharma AB Phone: + 45 2844 7567 E-mail: investor.relations@synactpharma.com About SynAct Pharma AB SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For further information: https://synactpharma.com/. This information is information that SynAct Pharma is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-08-20 07:30 CEST. Attachments SynAct Pharma Q2 2026 Interim Report

财报临床3期临床2期

2026-08-19

·synactpharma.com

SynAct Pharma progresses first commercial agreement on resomelagon for treatment of dengue in Brazil – term sheet signed

SynAct Pharma AB (publ) (”SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announces that the company has signed a term sheet and will initiate contract negotiations for a co-development and commercialization partnership with Hipolabor Farmacêutica LTDA (“Hipolabor”) for treatment of dengue and other viral infections in Brazil. Brazil is the world’s largest dengue market. The agreement will fully leverage Hipolabor’s proven regulatory, supply, distribution and commercial capabilities in Brazil needed to respond to the nature of the viral infections. SynAct retains full control of resomelagon to ensure freedom to operate for global partnering across indications. Based on positive development in the RESOVIR collaboration and underlining the potential that dengue and other arboviral indications represent as a business in Brazil, SynAct has entered contract negotiations on a co-development and commercial license agreement with Hipolabor – term sheet signed – to gain full leverage of local, proven regulatory, supply, distribution and commercial contracting capabilities. An agreement with Hipolabor marks an important step toward the first commercial partnership for resomelagon and provides a clear path to scale development in the world’s largest dengue market. More broadly, it underlines, without limiting, the significant business development potential of resomelagon across SynAct’s strategic focus areas and will not interfere with stated ambitions or abilities to strike global and/or regional deals on RA and autoimmune disorders. “We have been in discussion with Hipolabor for some time and we are impressed with their ability to scale their business to success. Their manufacturing, contracting and distribution capabilities fit very well with a shared vision for a successful introduction of resomelagon for dengue treatment in Brazil,” says Jeppe Øvlesen, Chief Executive Officer of SynAct Pharma. “The timing of entering into an agreement is great. It brings the right resources into the specific project for dengue in Brazil, while we are fully focused on establishing the global future for our autoimmune disease program following the ADVANCE readout in June.” Foundationally, the collaboration is based on the ongoing development program, RESOVIR-2, and the ongoing activities in SynAct’s research collaboration RESOVIR – update to be provided in the SynAct Q2 2026 announcement. “Dengue virus is a major concern for public health in Brazil. We firmly believe in resomelagon as a potential safe and effective treatment for patients across the country dealing with the effects of dengue virus,” said Renato Alves, Chief Executive Officer of Hipolabor. The parties have agreed to the following key terms. The definitive agreement is to be completed in the coming months. Commercial license agreement with a 50-50 profit share agreement and additional sales milestones of the initial USD 200m accumulated net sales. Co-development arrangement with a 50-50 split on development cost to bring resomelagon to approval in Brazil for the treatment of dengue. SynAct retains full control of resomelagon and the freedom to operate for cross-indication and cross-territory considerations. Together, SynAct and Hipolabor have a unique opportunity for success in Brazil. With more than 100 product filings, Hipolabor will leverage its clinical and regulatory team to support discussions with Brazil’s national health agency (ANVISA), review filings, and scale development programs. In addition, Hipolabor will leverage its nationwide distribution and contracting business to make resomelagon available to hospitals and clinics nationwide. Soft money options will be actively pursued through Brazilian and international organizations focused on dengue and other viral infections. Subject to separate supply agreement negotiations, Hipolabor will have the opportunity to provide competitive drug manufacturing and packaging for national and potential global distribution. About Hipolabor Hipolabor is one of the largest pharmaceutical companies in Brazil, with more than 40 years of history and commitment to health. With a portfolio consisting of more than 100 drug registrations — including injectables, solids, semi-solids, and liquids — the company operates strongly in the hospital and outpatient market, always focusing on offering safe, effective, and accessible solutions to the population. Hipolabor is the largest manufacturer of injectable generics in Brazil and occupies the 10th position in the national ranking of generic drug industries, according to the 2024 ANVISA Yearbook. More than 1,200 employees are distributed in three units: two manufacturing parks and a storage center, which operate in harmony to ensure efficiency, agility and quality at all stages of Hipolabor’s production chain. https://www.hipolabor.com.br/ About Dengue Dengue is a viral infection caused by the dengue virus (DENV), which is transmitted to humans through the bite of infected mosquitoes. About half of the world's population is now at risk of dengue, with an estimated 100–400 million infections occurring each year. Dengue is found in tropical and sub-tropical climates worldwide, mostly in urban and semi-urban areas. While many DENV infections are asymptomatic or produce only mild illness, DENV can occasionally cause more severe cases, and even death. Prevention and control of dengue rely on vector control. There is no specific treatment for dengue/severe dengue, and early detection and access to proper medical care greatly lower fatality rates of severe dengue. In the last 10 years, the number of dengue cases in Brazil has increased manyfold from 0.5m cases in 2017 to 3.8m in 2025, and cases vary greatly from year to year. 2024 reached a historic peak of 10m cases, and 2026, with 1.2m cases, reached the lowest number in the past five years. Approximately half of the cases are confirmed by lab tests. Between 0.05% and 0.08% of cases turn severe with more than 50% ending fatally. Source: https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue accessed on 13 August 2026; PAHO, Integrated Arbovirus Platform (PIA), data registered up to week 31 of 2026 For further information, please contact: Jeppe Øvlesen CEO, SynAct Pharma AB Phone: + 45 2844 7567 E-mail: investor.relations@synactpharma.com About SynAct Pharma AB SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For further information: https://synactpharma.com/. This information is information that SynAct Pharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-08-19 07:00 CEST. Attachments SynAct Pharma progresses first commercial agreement on resomelagon for treatment of dengue in Brazil – term sheet signed

引进/卖出

2026-08-05

·synactpharma.com

SynAct Pharma receives favorable US patent decision for immediate-release resomelagon tablet formulation

SynAct Pharma AB (publ) (“SynAct”) today announced that the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) has issued a favorable Decision on Appeal in U.S. patent application No. 18/065,702, Appeal No. 2026-000924, relating to an immediate-release solid oral dosage formulation of resomelagon (AP1189 acetate). The decision is an important step in SynAct’s strategy to strengthen the intellectual property protection around resomelagon. The appeal concerned whether it was obvious to formulate resomelagon as an immediate-release tablet designed to dissolve rapidly in acidic gastric conditions and support fast absorption. SynAct argued that this was not routine, given the compound’s known sensitivity under acidic conditions, and the PTAB supported SynAct’s position on obviousness. “This decision is highly important for SynAct and confirms the scientific and formulation work behind resomelagon. Developing an immediate-release oral tablet formulation of resomelagon has been neither a routine nor an obvious exercise. The PTAB decision supports that position and strengthens our long-term IP strategy for resomelagon,” said Thomas Boesen, Chief Operating Officer of SynAct Pharma. SynAct has previously announced that the USPTO has issued U.S. patent 12,239,631 covering the crystal form of resomelagon and U.S. patent 12,661,336, which includes patent term adjustment extending the term of that patent until July 2, 2044. The PTAB decision adds another important element to SynAct’s overall intellectual property strategy for resomelagon. Resomelagon (AP1189) is SynAct’s lead drug candidate and is being developed as an oral, once-daily selective melanocortin agonist across two main development tracks: rheumatoid arthritis (RA) and host-directed therapy in viral infections. In RA, resomelagon is being evaluated as a combination with first-line methotrexate therapy, while in viral infections SynAct is evaluating resomelagon’s potential to resolve excessive inflammation in patients with severe viral disease, including respiratory viral infections and Dengue. For further information, please contact: Jeppe Øvlesen CEO, SynAct Pharma AB Phone: + 45 2844 7567 E-mail: investor.relations@synactpharma.com About SynAct Pharma AB SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For further information: https://synactpharma.com/. Attachments SynAct Pharma receives favorable US patent decision for immediate-release resomelagon tablet formulation

专利侵权

100 项与 Resomelagon 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
流感病毒感染	临床2期	波斯尼亚和黑塞哥维那	SynAct Pharma ApS	2026-05-01
流感病毒感染	临床2期	黑山	SynAct Pharma ApS	2026-05-01
流感病毒感染	临床2期	新西兰	SynAct Pharma ApS	2026-05-01
流感病毒感染	临床2期	塞尔维亚	SynAct Pharma ApS	2026-05-01
呼吸功能不全	临床2期	波斯尼亚和黑塞哥维那	SynAct Pharma ApS	2026-05-01
呼吸功能不全	临床2期	黑山	SynAct Pharma ApS	2026-05-01
呼吸功能不全	临床2期	新西兰	SynAct Pharma ApS	2026-05-01
呼吸功能不全	临床2期	塞尔维亚	SynAct Pharma ApS	2026-05-01
病毒性呼吸道感染	临床2期	波斯尼亚和黑塞哥维那	SynAct Pharma ApS	2026-05-01
病毒性呼吸道感染	临床2期	黑山	SynAct Pharma ApS	2026-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04004429 (BEGIN, CTgov)	临床2期	类风湿关节炎	105	50 mg AP1189 (50 mg AP1189)	鹹衊醖範衊壓醖壓範網 = 鹹觸遞獵淵壓鹽鏇網鑰醖衊觸網網鹽積築衊簾 (繭壓淵憲鏇廠淵範壓憲, 鹹窪簾構醖醖憲鏇膚遞 ~ 觸繭願艱築憲繭繭積壓) 更多	-	2024-07-10
				AP1189 (100 mg AP1189)	鹹衊醖範衊壓醖壓範網 = 鑰艱製窪鬱鑰艱廠觸鬱醖衊觸網網鹽積築衊簾 (繭壓淵憲鏇廠淵範壓憲, 觸壓窪選觸糧網簾鏇簾 ~ 窪艱窪窪觸選襯獵齋觸) 更多
NCT05516979 (EXPAND，SynAct-CS007, NEWS 1 \| NEWS 2)	临床2期	类风湿关节炎	55	Resomelagon	膚餘顧簾壓繭壓簾鬱糧(艱鏇淵網鹽簾積範鑰醖) = 夢遞廠獵艱鏇鬱夢膚鹹壓蓋鹽遞夢觸鑰簾壓齋 (繭範襯膚窪膚鏇憲醖鑰 ) 更多	积极	2024-02-22
				安慰剂	膚餘顧簾壓繭壓簾鬱糧(艱鏇淵網鹽簾積範鑰醖) = 夢憲遞壓獵簾製繭簾襯壓蓋鹽遞夢觸鑰簾壓齋 (繭範襯膚窪膚鏇憲醖鑰 ) 更多
NCT05516979 (EXPAND，SynAct-CS007, ACR2023 \| NEWS)	临床2期	类风湿关节炎	127	Resomelagon	廠廠鑰艱製鹽鏇鹹糧願(襯膚繭遞襯顧蓋範獵築) = 淵鏇窪蓋遞膚衊淵鑰壓醖齋觸壓鑰憲夢夢網選 (齋艱鬱蓋憲糧衊構鹹夢 )	不佳	2023-09-04
				安慰剂	廠廠鑰艱製鹽鏇鹹糧願(襯膚繭遞襯顧蓋範獵築) = 夢顧築築窪鹹齋窪鏇顧醖齋觸壓鑰憲夢夢網選 (齋艱鬱蓋憲糧衊構鹹夢 )